Retrospective analysis on efficacy of convalescent plasma in acute respiratory distress syndrome due to COVID-19
Palavras-chave:
COVID-19, Respiratory distress syndrome, COVID-19 serotherapy [supplementary concept]Resumo
BACKGROUND: Coronavirus disease 2019 (COVID-19) is an ongoing global health threat. However, currently, no standard therapy has been approved for the disease. OBJECTIVES: To evaluate the clinical effectiveness of convalescent plasma (CP) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19. DESIGN AND SETTING: Retrospective study conducted at Kayseri City Education and Research Hospital, Kayseri, Turkey. METHODS: The case group consisted of adult patients (> 18 years) with ARDS due to COVID-19 who received CP in combination with antiviral and supportive treatment. These patients were compared with others who only received antiviral and supportive treatment. RESULTS: During the study period, a total of 30 patients with ARDS due to COVID-19 were included. Eleven patients (36%) received CP in combination with antiviral and supportive treatment, whereas nineteen patients (64%) in the control group only received antiviral and supportive treatment. On admission, the median age, demographic and clinical data and initial laboratory test results were similar between the groups (P > 0.05). On the 14th day of treatment, the laboratory values remained similar between the groups (P > 0.05). The mortality rates were not significantly different between the groups. CONCLUSION: CP treatment did not affect mortality or lead to clinical improvement for COVID-19 patients with ARDS.
Downloads
Referências
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-
PMID: 32123347; https://doi.org/10.1038/s41564-020-0695-z.
Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Bio-medica: Atenei Parmensis. 2020;91(1):157-60. PMID: 32191675; https://doi.org/10.23750/abm.v91i1.9397.
World Health Organization (WHO). Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed in 2021 (May 13).
Ghareeb DA, Saleh SR, Nofal MS, et al. Potential therapeutic and pharmacological strategies for SARS-CoV2. J Pharm Investig. 2021:1-
PMID: 33688448; https://doi.org/10.1007/s40005-021-00520-4.
Özdemir Ö, Arsoy HEM. Convalescent (Immune) plasma therapy with all aspects: yesterday, today and COVID-19. Erciyes Med J. 2020;42(3):252-9. https://doi.org/10.14744/etd.2020.36528.
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80-90. PMID: 25030060; https://doi.org/10.1093/infdis/jiu396.
Sayinalp B, Çinar OE, Haznedaroğlu İC. Perspectives for immune plasma treatment of COVID-19. Turk J Med Sci. 2021;51(1):1-9. PMID: 32718128; https://doi.org/10.3906/sag-2005-410.
Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020;92(10):1890-901. PMID: 32293713; https://doi.org/10.1002/jmv.25882.
Ahn JY, Sohn Y, Lee SH, et al. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci. 2020;35(14):e149. PMID: 32281317; https://doi.org/10.3346/jkms.2020.35.e149.
Klassen SA, Senefeld JW, Johnson PW, et al. Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv [Preprint]. 2020:2020.07.29.20162917. PMID: 33140056; https://doi.org/10.1101 /2020.07.29.20162917.
Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA. 2021;325(12):1185-95. PMID: 33635310; https://doi.org/10.1001/jama.2021.2747.
ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-33. PMID: 22797452; https://doi.org/10.1001/jama.2012.5669.
T.C. Sağlık Bakanlığı. Sağlik Hizmetleri Genel Müdürlüğü. Kan ve Kan Ürünleri Dairesi Başkanlığı. COVİD-19 İmmün (konvalesan) Plazma Tedarik ve Klinik Kullanım Rehberi. Ankara, Türkiye: T.C. Sağlık Bakanlığı; 2020. Available from: https://ekmud.org.tr/files/uploads/files/covid-19-immun%20plazma%20 rehberi-v5-26_10_2020.pdf. Accessed in 2021 (Jun 7).
Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020;26(11):1708-13. PMID: 32934372; https://doi.org/10.1038/s41591-020-1088-9.
Perotti C, Baldanti F, Bruno R, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020;105(12):2834-40. PMID: 33256382; https://doi.org/10.3324/haematol.2020.261784.
Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(5):460-70. PMID: 32492084; https://doi.org/10.1001/jama.2020.10044. Erratum in: JAMA. 2020;324(5):519.
Gharbharan A, Jordans CCE, Geurtsvankessel C, et al. Convalescent plasma for COVID-19. A randomized trial. medRxiv. 2020. https://doi.org/10.1101/2020.07.01.20139857.
Downloads
Publicado
Como Citar
Edição
Seção
Licença

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.